var data={"title":"Raltitrexed (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Raltitrexed (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6894?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=raltitrexed-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Raltitrexed (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217007\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tomudex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217032\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, Antimetabolite (Antifolate)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217009\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Treatment should be administered only if WBC &gt;4,000/mm<sup>3</sup>, ANC &gt;2,000/mm<sup>3</sup>, and platelets &gt;100,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, advanced:</b> IV: 3 mg/m<sup>2</sup> once every 3 weeks in the absence of toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant pleural mesothelioma (off-label use):</b> IV: 3 mg/m<sup>2</sup> once every 3 weeks (in combination with cisplatin) until disease progression or unacceptable toxicity occurs (van Meerbeeck 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991417\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &gt;65 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 55 to 65 mL/minute: Reduce dose to 75% of usual dose once every 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 25 to 54 mL/minute: Reduce dose to percentage of dose equivalent to CrCl once every 4 weeks (eg, reduce dose to 25% of usual dose for CrCl of 25 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;25 mL/minute: Do not administer (use is contraindicated in severe renal impairment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988659\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Preexisting impairment: Use is not recommended in clinical jaundice or decompensated liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: No dosage adjustment necessary; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatotoxicity during treatment: Interrupt therapy until toxicity returns to grade 2 or lower.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062197\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20343878\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: </i> Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients (Griggs 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217033\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Delay dose in subsequent cycles until recovery from toxicity. May consider administering leucovorin if appropriate. Once a dose reduction has been made, do not escalate dose in subsequent cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grade 4 gastrointestinal toxicity (diarrhea or mucositis) or grade 3 gastrointestinal toxicity in combination with grade 4 hematologic toxicity: Discontinue therapy and manage with supportive measures (consider administering leucovorin).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grade 3 hematologic toxicity (neutropenia or thrombocytopenia) or grade 2 gastrointestinal toxicity (diarrhea or mucositis): Reduce dose by 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grade 4 hematologic toxicity (neutropenia or thrombocytopenia) or grade 3 gastrointestinal toxicity (diarrhea or mucositis): Reduce dose by 50%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11391901\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution, as disodium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tomudex: 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234288\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216987\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as an infusion over 15 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When used in combination with cisplatin for malignant pleural mesothelioma (off-label use), administer raltitrexed first, followed by cisplatin (van Meerbeeck 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133463\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (meets NIOSH 2016 criteria). This medication is not on the NIOSH (2016) list; however, it meets the criteria for a hazardous drug. Drugs are classified as hazardous based on their properties; the properties of a hazardous drug include one or more of the following characteristics: carcinogenic, teratogenic (or other developmental toxicity), reproductive toxicity, organotoxic at low doses, genotoxic, and/or new agents with structural or toxicity profiles similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216986\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, advanced: </b>Treatment of advanced colorectal cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744897\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Malignant pleural mesothelioma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5977831\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Raltitrexed may be confused with methotrexate, PEMEtrexed, PRALAtrexate.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tomudex may be confused with Temodal.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216976\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (57% to 58%; grades 3/4: &le;12%), diarrhea (37% to 38%; grades 3/4: 11%), vomiting (37% to 38%; grades 3/4: &le;12%), anorexia (26% to 28%), abdominal pain (17% to 18%), constipation (13% to 15%), mucositis (12%; grades 3/4: &le;2%), stomatitis (11%; grades 3/4: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (20% to 22%; grade 3/4: 12% to 13%; nadir within 7 to 14 days, recovery by 21 days), anemia (15% to 18%; grades 3/4: 7% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (16% to 18%), increased serum ALT (14% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (46% to 49%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (10%), cardiac arrhythmia (3%; including sinus tachycardia, supraventricular tachycardia, atrial fibrillation), cardiac abnormality (2%; including cardiac failure)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6%), dizziness (4% to 5%), chills (4%), malaise (4%), pain (4%), insomnia (3% to 4%), depression (3%), paresthesia (2% to 3%), hypertonia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (6%), diaphoresis (3% to 4%), cellulitis (3%), pruritus (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (6% to 7%), weight loss (6%), hypokalemia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (6%), dyspepsia (6%), flatulence (2% to 3%), xerostomia (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (5% to 6%; grades 3/4: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (2% to 3%; grades 3/4: 2%), increased serum alkaline phosphatase (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (3%), sepsis (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (3%), arthralgia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (6% to 8%), cough (5%), dyspnea (4% to 5%), pharyngitis (4% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Desquamation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216990\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to raltitrexed or any component of the formulation; severe renal and/or hepatic impairment; pregnancy or breast-feeding; use in women who may become pregnant; use in children.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216974\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Neutropenia, leukopenia, anemia, and thrombocytopenia may occur; neutropenia and thrombocytopenia may be severe. Bone marrow suppression is typically mild to moderate and generally occurs 7 to 14 days after treatment; recovery usually occurs by day 21. Use with caution in patients with preexisting bone marrow suppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Nausea, vomiting and diarrhea are common; mucositis and stomatitis may also occur. Severe diarrhea with concomitant hematologic toxicity (neutropenia) may be life-threatening and may require discontinuation or subsequent dose reduction. Nausea and vomiting are usually responsive to antiemetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malaise/weakness: May cause malaise/weakness; caution patients concerning operation of machinery/driving.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. Use is contraindicated in severe impairment and is not recommended in clinical jaundice or decompensated liver disease. Therapy interruption is required in patients with hepatotoxicity; may reinitiate therapy when hepatic enzymes return to grade 2 or lower. Asymptomatic and self-limiting reversible ALT and AST elevations may also occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with mild to moderate renal impairment (clearance is reduced ~50%). Use is contraindicated in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients. Monitor closely, especially for gastrointestinal toxicity such as diarrhea or mucositis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation therapy recipients: Use with caution in patients who have received prior radiation therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299979\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216978\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10087&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Folic Acid: May diminish the therapeutic effect of Raltitrexed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Raltitrexed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levomefolate: May diminish the therapeutic effect of Raltitrexed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: May diminish the therapeutic effect of Raltitrexed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Raltitrexed. Specifically, the folic acid contained in multivitamins is responsible for this potential interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrimethamine: May enhance the adverse/toxic effect of Raltitrexed.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216992\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use is contraindicated in women who are or may become pregnant during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adverse events were observed in animal reproduction studies. Pregnancy should be excluded prior to treatment, and should be avoided during treatment and for at least 6 months following treatment (including women with male partners receiving treatment). Pregnant women should not handle this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20608713\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use in nursing women is contraindicated by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216993\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid folic acid, folinic acid (leucovorin calcium), and multivitamins with folic acid close to and during administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216982\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (at baseline, prior to each treatment, or weekly if gastrointestinal toxicity observed); hepatic function tests and serum creatinine (at baseline and prior to each treatment); signs of gastrointestinal toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216973\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Raltitrexed is a folate analogue that selectively inhibits thymidylate synthase, blocking purine synthesis. This results in an overall inhibition of DNA synthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216989\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: 548 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 93%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Undergoes extensive intracellular metabolism to active polyglutamate forms; appears to be little or no systemic metabolism of the drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Triphasic; Beta: ~2 hours; Terminal: 198 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~50% as unchanged drug); feces (~15%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51220398\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function impairment: Plasma clearance is reduced approximately 50% in patients with mild to moderate impairment (CrCl 25 to 65 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic function impairment: Mild to moderate impairment results in a reduction in plasma clearance of less than 25%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216994\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Tomudex (AR, AT, AU, BE, BG, BR, CH, CZ, EE, ES, FR, GB, HN, HU, IE, IS, IT, KR, LU, MX, NL, NO, PL, PT, RU, SG, TR, UY, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bottomley A, Coens C, Efficace F, et al, &ldquo;Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma,&rdquo; <i>J Clin Oncol</i>, 2007, 25(36):5770-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltitrexed-united-states-not-available-drug-information/abstract-text/18089874/pubmed\" target=\"_blank\" id=\"18089874\">18089874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bottomley A, Gaafar R, Manegold C, et al, &ldquo;Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study,&rdquo; <i>J Clin Oncol</i>, 2006, 24(9):1435-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltitrexed-united-states-not-available-drug-information/abstract-text/16446322/pubmed\" target=\"_blank\" id=\"16446322\">16446322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltitrexed-united-states-not-available-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massacesi C, Santini D, Rocchi MB, et al, &ldquo;Raltitrexed-Induced Hepatotoxicity: Multivariate Analysis of Predictive Factors,&rdquo; <i>Anticancer Drugs</i>, 2003, 14(7):533-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltitrexed-united-states-not-available-drug-information/abstract-text/12960737/pubmed\" target=\"_blank\" id=\"12960737\">12960737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reni M, Pasetto L, Aprile G, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. <i>Br J Cancer.</i> 2006;94(6):786-791.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltitrexed-united-states-not-available-drug-information/abstract-text/16508631/pubmed\" target=\"_blank\" id=\"16508631\">16508631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomudex (raltitrexed) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. <i>Br J Cancer. </i>2003;88(8):1180-1184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltitrexed-united-states-not-available-drug-information/abstract-text/12698181/pubmed\" target=\"_blank\" id=\"12698181\">12698181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Cutsem E, Cunningham D, Maroun J, et al, &quot;Raltitrexed: Current Clinical Status and Future Directions,&quot; <i>Ann Oncol</i>, 2002, 13(4):513-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltitrexed-united-states-not-available-drug-information/abstract-text/12056700/pubmed\" target=\"_blank\" id=\"12056700\">12056700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16192580\"></a>van Meerbeeck JP, Gaafar R, Manegold C, et al, &ldquo;Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada,&rdquo; <i>J Clin Oncol</i>, 2005, 23(28):6881-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/raltitrexed-united-states-not-available-drug-information/abstract-text/16192580/pubmed\" target=\"_blank\" id=\"16192580\">16192580</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10087 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F217007\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F217032\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F217009\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991417\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988659\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062197\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20343878\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F217033\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F11391901\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11234288\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F216987\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133463\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F216986\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744897\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5977831\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216976\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F216990\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F216974\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299979\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F216978\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F216992\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20608713\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F216993\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F216982\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F216973\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F216989\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51220398\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F216994\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10087|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=raltitrexed-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Raltitrexed (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}